Current position

Ray Dalio’s Amgen Inc (AMGN) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2009Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares166.23KHighest verified quarter-end share count
Quarters reported40Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Amgen Inc in Q2 2009. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 21.87K shares. The latest verified filing showed: Bought 48.0% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 48.0% more+7.10K shares · 21.87K shares reported after the change
Filing context

Quarter-end price $362.12 · Estimated holding basis $345.29

Q1 2026
Bought 389.2% more+11.75K shares · 14.77K shares reported after the change
Filing context

Quarter-end price $351.85 · Estimated holding basis $337.21

Q4 2025
Sold 73.3% of the position−8.28K shares · 3.02K shares remained
Filing context

Quarter-end price $327.31 · Estimated holding basis $280.23

Q3 2025
Bought 51.9% more+3.86K shares · 11.30K shares reported after the change
Filing context

Quarter-end price $282.20 · Estimated holding basis $280.23

Q2 2025
New position+7.44K shares · 7.44K shares reported
Filing context

Quarter-end price $279.21 · Estimated holding basis $279.21

Q1 2025
Sold the entire position−1.42K shares · No shares reported at quarter-end
Portfolio importance

How important is Amgen Inc in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#378of 997 reported positions
Peak portfolio weight0.2%Q1 2023
Best historical rank#49Q2 2013
At peak importanceQ1 2023
AMGN
0.2%
Largest holding
5.3%
Cross-investor discovery

Who else owns Amgen Inc?

Also reported by 1 other tracked investor in their latest verified filings.

Joel GreenblattGotham Asset Management
AMGN0.0% of reported portfolio
Explore Amgen Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$375.652026-09-15

Market context only; not an investor transaction price.

Latest filing quarter-end price$362.12Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$345.29Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.